




RealRate

PHARMACEUTICAL 2019

ENDONOVO THERAPEUTICS INC.
Rank 279 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2019

ENDONOVO THERAPEUTICS INC. Rank 279 of 371

The relative strengths and weaknesses of ENDONOVO THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDONOVO THERAPEUTICS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 338% points. The greatest weakness of ENDONOVO THERAPEUTICS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 157% points.

The company's Economic Capital Ratio, given in the ranking table, is -389%, being 58% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	382
Cost of Goods Sold	13
Intangible Assets	3,853
Liabilities, Current	15,479
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	4,230
Other Liabilities	155
Other Net Income	-2,277
Property and Equipment	6.7
Research and Development	0
Revenues	83
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	4,242
Liabilities	15,634
Expenses	4,243
Stockholders Equity	-11,392
Net Income	-6,436
Comprehensive Net Income	-6,436
Economic Capital Ratio	-389%

